Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance (Q38884246)

7 September 2017

title

Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance (English)

1 reference

7 September 2017

0 references

anti-retroviral agent

0 references

1 reference

9

Peter Mugyenyi

1 reference

7 September 2017

Paul J Weidle

1

1 reference

7 September 2017

Samuel Malamba

2

1 reference

7 September 2017

Raymond Mwebaze

3

1 reference

7 September 2017

Catherine Sozi

4

1 reference

7 September 2017

Gideon Rukundo

5

1 reference

7 September 2017

Robert Downing

6

1 reference

7 September 2017

Debra Hanson

7

1 reference

7 September 2017

Dorothy Ochola

8

1 reference

7 September 2017

Jonathan Mermin

10

1 reference

7 September 2017

Badara Samb

11

1 reference

7 September 2017

Eve Lackritz

12

1 reference

7 September 2017

language of work or name

English

0 references

publication date

1 July 2002

1 reference

7 September 2017

1 reference

7 September 2017

volume

360

1 reference

7 September 2017

issue

9326

1 reference

7 September 2017

page(s)

34-40

1 reference

PUBLIC HEALTH: HIV/AIDS Treatment for Millions

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909330-3

7 January 2021

AIDS meeting. Companies, donors pledge to close gap in AIDS treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909330-3

7 January 2021

Antiretrovirals for developing world

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909330-3

7 January 2021

Community-based approaches to HIV treatment in resource-poor settings

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909330-3

7 January 2021

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909330-3

7 January 2021

A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909330-3

7 January 2021

Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909330-3

7 January 2021

A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A S

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909330-3

7 January 2021

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909330-3

7 January 2021

Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909330-3

7 January 2021

Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909330-3

7 January 2021

Development and significance of resistance to protease inhibitors in HIV-1-infected adults under triple-drug therapy in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909330-3

7 January 2021

Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909330-3

7 January 2021

10.1016/S0140-6736(02)09330-3

Identifiers

DOI

1 reference

7 September 2017

1 reference